N-Glycosylated type Ⅱ collagen peptides as therapeutic saccharide vaccines for rheumatoid arthritis  

作　　者：Dake Liu Shuyan Liu Fanlei Hu Zhongtang Li Zhongjun Li 

机构地区：[1]State Key Laboratory of Natural and Biomimetic Drugs,School of Pharmaceutical Sciences,Peking University,Beijing 100191,China [2]Department of Rheumatology and Immunology,Peking University People’s Hospital,Beijing 100044,China

出　　处：《Chinese Chemical Letters》2024年第5期197-200,共4页中国化学快报（英文版）

基　　金：supported by the National Natural Science Foundation of China(Nos.81930097,21977005,82151223);supported by the National Key R&D Program of China(No.2022YFF1203005).

摘　　要：The interaction among type Ⅱ collagen(CⅡ),human DR4 major histocompatibility complex type Ⅱ molecule(MHC Ⅱ)and T-cell receptor(TCR)is associated with the development of rheumatoid arthritis(RA).The activation of T cells can be reduced through exposure to modified CⅡ(263-272)glycopeptide fragment via competitive inhibition with self-antigen.In this work,30 peptides based on the sequence of CⅡ(263-272)were prepared and evaluated for their binding to DR4 protein by surface plasmon resonance(SPR)assay.The effect on the secretion of pro-inflammatory factors by the spleen cells in collagen induced rheumatoid arthritis(CIA)mouse was also investigated.Two N-glycosylated CⅡ peptides were identified to have strong binding to the human recombinant DR4 protein and weak proinflammatory effect.These glycopeptides could be developed as therapeutic saccharide vaccines for the treatment of rheumatoid arthritis(RA).

关 键 词：Rheumatoid arthritis TypeⅡcollegan GLYCOSYLATION N-Glycosylated altered peptides Saccharide vaccines 

分 类 号：TQ460.1[化学工程—制药化工]